Stocks · US
CORT
XNAS
Corcept Therapeutics Inc.
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E242.09x
P/B18.69x
P/S15.88x
EPS$0.50
ROE7.72%
ROA6.13%
Dividend yield0.00%
EV/EBITDA1,549.05x
Debt/Equity0.00
Free cash flow$107M
Returns and 52-week range
1W+4.21%
1M+7.12%
3M+28.65%
6M+186.81%
1Y+35.64%
YTD+213.01%
52W high$126.38
52W low$28.66
From 52W high-5.39%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| 트위스트 바이오사이언스 | $13.6B | — | 30.49 | +33.88% |
| Icon Plc | $13.0B | 38.45 | 6.71 | -1.92% |
| Exelixis Inc | $14.6B | 16.94 | 7.91 | -1.15% |
| BridgeBio Pharma, Inc. Common Stock | $12.9B | — | — | -10.53% |
| Neurocrine Biosciences Inc | $14.7B | 20.78 | 3.97 | -6.51% |
| 10X 지노믹스 | $12.7B | — | 15.43 | +28.75% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.